Skip to main content
Erschienen in: Metabolic Brain Disease 6/2016

09.09.2015 | Original Article

Where are we going? Translational research in hepatic encephalopathy

verfasst von: Piero Amodio, Sara Montagnese, Kevin Mullen, James G. Orr, Hendrik Vilstrup

Erschienen in: Metabolic Brain Disease | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Translational medicine, rather than being a unidirectional clinical utilization of basic research discoveries, should be a bidirectional process of cross-fertilization between basic science, medical knowledge and clinical utilization. While steps and processes differ across these branches of research, clear language and proper definitions are prerequisites for effective interaction of researchers to facilitate knowledge development. With respect to Hepatic Encephalopathy, at first glance the areas which require development are around prevention, both to reduce the risk of relapse following an episode of overt HE and to reduce the risk of the first episode of HE. In addition, shortening the duration of episodes of overt HE may also be relevant. Comparisons of treatments and combinations of treatments, acting by different but potentially synergistic mechanisms, are reasonable targets for both basic and applied research.
Literatur
Zurück zum Zitat Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am.J.Gastroenterol. 107:1043–1050. doi:10.1038/ajg.2012.113 CrossRefPubMed Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am.J.Gastroenterol. 107:1043–1050. doi:10.​1038/​ajg.​2012.​113 CrossRefPubMed
Zurück zum Zitat Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140:478–487. doi:10.1053/j.gastro.2010.08.061 CrossRefPubMed Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140:478–487. doi:10.​1053/​j.​gastro.​2010.​08.​061 CrossRefPubMed
Zurück zum Zitat Berni E, Bannister C, Poole CD, Conway P, Nanuwa K, Currie CJ (2014) PWE-154 the first evaluation of the relationship between the chronic liver disease questionnaire and the Eq-5d index in hepatic encephalopathy patients treated with rifaximin-a. Gut 63:A192. doi:10.1136/gutjnl-2014-307263.414 CrossRef Berni E, Bannister C, Poole CD, Conway P, Nanuwa K, Currie CJ (2014) PWE-154 the first evaluation of the relationship between the chronic liver disease questionnaire and the Eq-5d index in hepatic encephalopathy patients treated with rifaximin-a. Gut 63:A192. doi:10.​1136/​gutjnl-2014-307263.​414 CrossRef
Zurück zum Zitat Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N.Engl.J.Med 362:1071–1081. doi:10.1056/NEJMoa0907893 CrossRefPubMed Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N.Engl.J.Med 362:1071–1081. doi:10.​1056/​NEJMoa0907893 CrossRefPubMed
Zurück zum Zitat Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J.Health Econ. 21:271–292CrossRefPubMed Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J.Health Econ. 21:271–292CrossRefPubMed
Zurück zum Zitat Briggs A, Claxton K, Sculpher M (2006) Decision Modelling for Health Eonomic Evaluation Oxford. University Press, New York Briggs A, Claxton K, Sculpher M (2006) Decision Modelling for Health Eonomic Evaluation Oxford. University Press, New York
Zurück zum Zitat Campagna F, Montagnese S, Schiff S, Biancardi A, Mapelli D, Angeli P, Poci C, Cillo U, Merkel C, Gatta A, Amodio P (2014) Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl 20:977–986. doi:10.1002/lt.23909 CrossRefPubMed Campagna F, Montagnese S, Schiff S, Biancardi A, Mapelli D, Angeli P, Poci C, Cillo U, Merkel C, Gatta A, Amodio P (2014) Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl 20:977–986. doi:10.​1002/​lt.​23909 CrossRefPubMed
Zurück zum Zitat Campagna F, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P (2015) Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study. Liver Int 35:1524–1532. doi:10.1111/liv.12635 CrossRefPubMed Campagna F, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P (2015) Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study. Liver Int 35:1524–1532. doi:10.​1111/​liv.​12635 CrossRefPubMed
Zurück zum Zitat Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Gines P, Bernardi M, Arroyo V (2014) Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J.Hepatol. 60:275–281. doi:10.1016/j.jhep.2013.10.004 CrossRefPubMed Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Gines P, Bernardi M, Arroyo V (2014) Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J.Hepatol. 60:275–281. doi:10.​1016/​j.​jhep.​2013.​10.​004 CrossRefPubMed
Zurück zum Zitat Courson A, Jones GM, Twilla JD (2015) Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J.Pharm.Pract. doi:10.1177/0897190014566312 PubMed Courson A, Jones GM, Twilla JD (2015) Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J.Pharm.Pract. doi:10.​1177/​0897190014566312​ PubMed
Zurück zum Zitat Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, New York
Zurück zum Zitat Galen RS, Gambino SR (1975) Beyond normality: the predictive value and efficiency of medical diagnoses. Wiley, New York Galen RS, Gambino SR (1975) Beyond normality: the predictive value and efficiency of medical diagnoses. Wiley, New York
Zurück zum Zitat Gray AM, Clarke PM, Wostenholme IL, & wordsworth S (2011) Applied Methods of Cost-Effectiveness Analysis in Health CareOxford University Press, Oxford Gray AM, Clarke PM, Wostenholme IL, & wordsworth S (2011) Applied Methods of Cost-Effectiveness Analysis in Health CareOxford University Press, Oxford
Zurück zum Zitat Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V (1999) AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J.Am.Coll.Cardiol 34:1348–1359CrossRefPubMed Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V (1999) AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J.Am.Coll.Cardiol 34:1348–1359CrossRefPubMed
Zurück zum Zitat Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B (2014) Updated national and international hypertension guidelines: a review of current recommendations. Drugs 74:2033–2051CrossRefPubMedPubMedCentral Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B (2014) Updated national and international hypertension guidelines: a review of current recommendations. Drugs 74:2033–2051CrossRefPubMedPubMedCentral
Zurück zum Zitat Morris S, Devlin N, Parkin D (2007) Economic analysis in health Care. Wiley, Chichester Morris S, Devlin N, Parkin D (2007) Economic analysis in health Care. Wiley, Chichester
Zurück zum Zitat Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559. doi:10.1002/hep.21533 CrossRefPubMed Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559. doi:10.​1002/​hep.​21533 CrossRefPubMed
Zurück zum Zitat Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, & Scharschmidt BF(2014) Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology, 59:1073–1083. doi: 10.1002/hep.26611 CrossRefPubMedPubMedCentral Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, & Scharschmidt BF(2014) Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology, 59:1073–1083. doi: 10.​1002/​hep.​26611 CrossRefPubMedPubMedCentral
Zurück zum Zitat Roman E, Cordoba J, Torrens M, Torras X, Villanueva C, Vargas V, Guarner C, Soriano G (2011) Minimal hepatic encephalopathy is associated with falls. AmJGastroenterol 106:476–482. doi:10.1038/ajg.2010.413 Roman E, Cordoba J, Torrens M, Torras X, Villanueva C, Vargas V, Guarner C, Soriano G (2011) Minimal hepatic encephalopathy is associated with falls. AmJGastroenterol 106:476–482. doi:10.​1038/​ajg.​2010.​413
Zurück zum Zitat Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen JM, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment.Pharmacol.Ther. 34:853–861. doi:10.1111/j.1365-2036.2011.04808.x CrossRefPubMed Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen JM, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment.Pharmacol.Ther. 34:853–861. doi:10.​1111/​j.​1365-2036.​2011.​04808.​x CrossRefPubMed
Zurück zum Zitat Schiff S, Vallesi A, Mapelli D, Orsato R, Pellegrini A, Umilta C, Gatta A, Amodio P (2005) Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 20:381–392. doi:10.1007/s11011-005-7922-4 CrossRefPubMed Schiff S, Vallesi A, Mapelli D, Orsato R, Pellegrini A, Umilta C, Gatta A, Amodio P (2005) Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study. Metab Brain Dis 20:381–392. doi:10.​1007/​s11011-005-7922-4 CrossRefPubMed
Zurück zum Zitat Schomerus H, Hamster W (2001) Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 16:37–41CrossRefPubMed Schomerus H, Hamster W (2001) Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 16:37–41CrossRefPubMed
Zurück zum Zitat Sharma BC, Sharma P, Agrawal A, Sarin SK (2009) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137(885–91):891. doi:10.1053/j.gastro.2009.05.056 Sharma BC, Sharma P, Agrawal A, Sarin SK (2009) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137(885–91):891. doi:10.​1053/​j.​gastro.​2009.​05.​056
Zurück zum Zitat Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT (2009) Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 15:184–192. doi:10.1002/lt.21593 CrossRefPubMed Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT (2009) Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl 15:184–192. doi:10.​1002/​lt.​21593 CrossRefPubMed
Zurück zum Zitat Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver. Hepatology 60:715–735. doi:10.1002/hep.27210 CrossRefPubMed Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the american association for the study of liver diseases and the european association for the study of the liver. Hepatology 60:715–735. doi:10.​1002/​hep.​27210 CrossRefPubMed
Metadaten
Titel
Where are we going? Translational research in hepatic encephalopathy
verfasst von
Piero Amodio
Sara Montagnese
Kevin Mullen
James G. Orr
Hendrik Vilstrup
Publikationsdatum
09.09.2015
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 6/2016
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-015-9728-3

Weitere Artikel der Ausgabe 6/2016

Metabolic Brain Disease 6/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.